Literature DB >> 1260255

Septic complications of pancreatitis.

S G Grace, D State.   

Abstract

Over an 11-year period 693 patients with acute pancreatitis and 317 with chronic pancreatitis were seen at the Harbor General Hospital. Review of these cases revealed 9 patients with primary pancreatic lesser sac abscess and 11 with secondary abscess. The appropriate management for pancreatic abscess, whether primary or secondary, is early recognition and drainage; multiple drainage procedures may be necessary. Broad spectrum antibodies appear to be helpful and should be used until cultures indicate more appropriate antibiotic therapy. Successful management involves prolonged hospitalization, but contrary to previous reports the success rate is surprisingly high. Eight out of 9 patients with primary abscess and 8 out of 11 patients with secondary abscess survived.

Entities:  

Mesh:

Year:  1976        PMID: 1260255     DOI: 10.1002/bjs.1800630316

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Review of general surgery 1976.

Authors:  H Ellis
Journal:  Postgrad Med J       Date:  1977-04       Impact factor: 2.401

Review 2.  Surgical treatment of acute pancreatitis.

Authors:  J H Ranson
Journal:  Dig Dis Sci       Date:  1980-06       Impact factor: 3.199

3.  Pancreatic abscess and other pus-harboring collections related to pancreatitis: a review of 108 cases.

Authors:  C Bassi; S Vesentini; F Nifosì; R Girelli; M Falconi; A Elio; P Pederzoli
Journal:  World J Surg       Date:  1990 Jul-Aug       Impact factor: 3.352

4.  The surgical management of pancreatic abscess.

Authors:  M M Mughal; J Bancewicz; M H Irving
Journal:  Ann R Coll Surg Engl       Date:  1987-03       Impact factor: 1.891

5.  Management of pancreatic abscesses.

Authors:  A Saxon; J T Reynolds; A Doolas
Journal:  Ann Surg       Date:  1981-11       Impact factor: 12.969

6.  Pancreatic abscess.

Authors:  P C Gartell
Journal:  J R Soc Med       Date:  1982-02       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.